What sample matrices are typically required for a comprehensive viral shedding study for an oncolytic virus?
For a robust assessment compliant with UK regulatory expectations, we analyze a panel of biological samples collected at multiple time points. This typically includes urine, feces, saliva, and blood (plasma or whole blood). Swabs from the conjunctiva, nasal cavity, and throat are also standard. The specific matrices depend on the viral vector, the route of administration, and the anticipated tropism of the therapy.
What is the standard assay technology used to quantify viral shedding, and what are the typical limits of quantification (LOQ)?
The industry standard for quantifying viral genetic material in shedding samples is quantitative PCR (qPCR) or droplet digital PCR (ddPCR). These methods offer high sensitivity and specificity. Our GxP-validated assays are designed to achieve a low limit of quantification, ensuring detection of even minimal shedding events.
How long does a typical preclinical viral shedding study take from initiation to final report?
The in-life phase duration is dictated by the study design, often lasting for several weeks post-dose to capture both acute and persistent shedding. Following the final sample collection, the bioanalytical phase, including sample processing, qPCR/ddPCR analysis, and data interpretation, requires a dedicated timeframe. A comprehensive, GxP-compliant report is then generated for inclusion in your regulatory submission package.
Are these studies required for all oncolytic virus programs targeting the UK market?
Yes, viral shedding and biodistribution data are a core component of the nonclinical safety data package required by the UK’s regulatory authority (MHRA) for all investigational gene therapies, including oncolytic viruses. These data are used to assess the potential risk of transmission to untreated individuals and to inform clinical trial protocols and risk management plans.
A comprehensive preclinical viral shedding analysis is a foundational component of the safety data package for oncolytic virus therapies submitted to the UK’s MHRA. This page outlines the technical design of these studies, focusing on quantitative PCR (qPCR) and droplet digital PCR (ddPCR) methodologies for quantifying viral material in various biological matrices. We discuss the importance of aligning study design with regulatory expectations to support a successful Clinical Trial Authorisation (CTA) application and de-risk the path toward an 18-24 month IND timeline.
Characterizing the potential for an oncolytic virus to be shed from a treated subject is a primary safety objective. The study design must be robust enough to detect, quantify, and determine the clearance kinetics of shed virus.
Key design considerations include:
-
Matrix Selection: A comprehensive panel of biological samples (e.g., urine, feces, saliva, blood) is collected to assess all potential routes of excretion.
-
Time Point Analysis: Samples are collected at multiple time points post-administration to profile the onset, peak, and duration of shedding.
-
Assay Validation: The quantitative assays (qPCR or ddPCR) used must be fully validated under GxP conditions to establish specificity, sensitivity, accuracy, and precision.
-
Data Interpretation: The results inform the risk assessment regarding potential transmission and guide the development of safety precautions for clinical trial staff and patient contacts.
The development of advanced therapies requires a deep commitment to safety and ethical conduct. As noted in recent scientific commentary, concerns over safety events should not halt progress but should reinforce the need for responsible development programs (PMID: 40643951). Rigorous safety assessments, including viral shedding analysis, are central to this principle.
Our work is supported by a >100,000 sq ft facility. In vivo studies are conducted in AAALAC International-accredited and USDA-registered facilities to ensure the highest standards of animal welfare. All study protocols are designed in strict accordance with the 3Rs (Replacement, Reduction, and Refinement).
The strategic value of a preclinical program is measured by its ability to predict clinical outcomes. Studies demonstrating the safety and efficacy of novel vectors in well-characterized translational models provide a strong foundation for clinical advancement (PMID: 22985273). A properly executed viral shedding study provides clear, quantitative data that directly informs the clinical risk assessment and management strategy, strengthening the overall regulatory submission. Franklin Biolabs has maintained a 100% IND/CTA success rate for our sponsors’ integrated programs since 2019, a record we are proud to continue since our brand launch in 2024.
